Upstream Bio Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Public

  • Employees
  • 75

Employees

  • Stock Symbol
  • UPB

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.15
  • (As of Monday Closing)

Upstream Bio General Information

Description

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 890 Winter Street
  • Suite 200
  • Waltham, MA 02451
  • United States
+1 (781)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 890 Winter Street
  • Suite 200
  • Waltham, MA 02451
  • United States
+1 (781)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Upstream Bio Stock Performance

As of 16-Nov-2026, Upstream Bio’s stock price is $2.15. Its current market cap is $118M with 54.8M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.15 $2.78 $2.12 - $33.68 $118M 54.8M 968K -$3.01

Upstream Bio Financials Summary

As of 30-Sep-2026, Upstream Bio has a trailing 12-month revenue of $2.87M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 28,290 1,096,140 1,043,284
Revenue 2,870 2,854 2,370 2,380
EBITDA (175,336) (160,188) (74,840) (24,642)
Net Income (163,944) (143,443) (62,806) (20,537)
Total Assets 245,992 353,772 481,719 117,198
Total Debt 789 1,269 1,834 45
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Upstream Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Upstream Bio‘s full profile, request access.

Request a free trial

Upstream Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Upstream Bio‘s full profile, request access.

Request a free trial

Upstream Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an init
Drug Discovery
Waltham, MA
75 As of 2025

Paris, France
 

Wilmington, DE
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Upstream Bio Competitors (92)

One of Upstream Bio’s 92 competitors is Abivax, a Formerly PE-Backed company based in Paris, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Abivax Formerly PE-Backed Paris, France
Ayala Pharmaceuticals Corporation Wilmington, DE
Equillium Formerly VC-backed La Jolla, CA
Mesoblast Corporation Melbourne, Australia
Mineralys Formerly VC-backed Radnor, PA
You’re viewing 5 of 92 competitors. Get the full list »

Upstream Bio Patents

Upstream Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260347487-A1 Methods of treating rhinosinusitis with nasal polyps Pending 28-Apr-2025
WO-2026231647-A1 Methods of treating rhinosinusitis with nasal polyps Pending 28-Apr-2025
US-12150991-B2 Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same Active 16-Jun-2023
US-20240173405-A1 Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same Active 16-Jun-2023
US-20250064929-A1 Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same Pending 16-Jun-2023 A61K39/39591
To view Upstream Bio’s complete patent history, request access »

Upstream Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Upstream Bio Investments (1)

Upstream Bio’s most recent deal was a Corporate Asset Purchase with Astellas Pharma (Verekitug Asthma Drug). The deal was made on 01-Oct-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Astellas Pharma (Verekitug Asthma Drug) 01-Oct-2021 Corporate Asset Purchase Buildings and Property
To view Upstream Bio’s complete investments history, request access »

Upstream Bio ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Upstream Bio’s complete esg history, request access »

Upstream Bio FAQs

  • When was Upstream Bio founded?

    Upstream Bio was founded in 2021.

  • Where is Upstream Bio headquartered?

    Upstream Bio is headquartered in Waltham, MA.

  • What is the size of Upstream Bio?

    Upstream Bio has 75 total employees.

  • What industry is Upstream Bio in?

    Upstream Bio’s primary industry is Drug Discovery.

  • Is Upstream Bio a private or public company?

    Upstream Bio is a Public company.

  • What is Upstream Bio’s stock symbol?

    The ticker symbol for Upstream Bio is UPB.

  • What is the current stock price of Upstream Bio?

    As of 16-Nov-2026 the stock price of Upstream Bio is $2.15.

  • What is the current market cap of Upstream Bio?

    The current market capitalization of Upstream Bio is $118M.

  • What is Upstream Bio’s current revenue?

    The trailing twelve month revenue for Upstream Bio is $2.87M.

  • Who are Upstream Bio’s competitors?

    Abivax, Ayala Pharmaceuticals, Equillium, Mesoblast, and Mineralys are some of the 92 competitors of Upstream Bio.

  • What is Upstream Bio’s annual earnings per share (EPS)?

    Upstream Bio’s EPS for 12 months was -$3.01.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process